##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 209 Download : 134

##plugins.themes.academic_pro.article.main##

Abstract

Papillary thyroid cancer is the commonest one among thyroid cancers. β - catenin is thought to be involved in thyroid cell to cell adhesion and proliferation. This study was aimed to determine β -catenin expression in benign and malignant tumors and its correlation to tumor differentiation. Methods: Fifty three paraffin blocks of malignant and benign thyroid samples were collected from patients underwent thyroidectomy. Paraffin blocks were stained with Rabbit monoclonal to β -catenin. Results: Most of papillary thyroid carcinomas subtypes are well differentiated (71%). Out of 15 cases of benign thyroid tumors, 11 cases showed a membranous staining (73.3%). Out of 38 cases of papillary thyroid carcinomas, 17 cases showed a membranous staining (44.7%). There was a significantly higher cytoplasmic staining in papillary thyroid carcinomas than benign lesions (39.5% vs 20%). There was no significant nuclear staining in benign lesions and papillary thyroid carcinomas. The membranous staining was significantly lost in cases of poorly differentiated and undifferentiated papillary thyroid carcinomas. Conclusion: β‑catenin shifting from the membrane to the cytoplasm in papillary thyroid carcinoma is helpful in its differentiation from benign lesions.

Keywords

β‑catenin immunohistochemistry papillary carcinoma thyroid

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Eaman Suud Khalifa. (2022). β‑catenin Immunohistochemical expression in papillary thyroid cancer versus benign thyroid lesions in a sample of Iraqi patients. Texas Journal of Medical Science, 6, 1–8. https://doi.org/10.62480/tjms.2022.vol6.pp1-8
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Khan A, Nose V. In: Lloyd RV, editor. Endocrine pathology: differential diagnosis and molecular advances, 2nd ed. New York: Springer 2010; p. 181–236.
  2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277- 300.
  3. Feldman AL, Eunhee SY. Rosai and Ackerman’s surgical pathology. JAMA 2012;307:201.
  4. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980‑2005. Cancer Epidemiol Biomarkers Prev 2009;18:784‑91
  5. Rotstein L. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol. 2009;99(4):186-8.
  6. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid. Cancer. 2007;110(1):38-46.
  7. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(S2):S37-43.
  8. Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforov YE. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope. 2013;123(4):1059-64.
  9. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High Prevalence of BRAF Mutations in Thyroid Cancer Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma. Cancer Res. 2003;63(7):1454-7. PMID:12670889
  10. Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B, et al. Expressions of CK‑19, NF‑kappaB, E‑cadherin, beta‑catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol 2011;9:187‑99.
  11. Barker N, Clevers H 2000 Catenins, Wnt signaling and cancer. Bioessays 22:961–965
  12. Polakis P. The many ways of Wnt in cancer. Curr Opin Genetics Dev. 2007;17(1):45- 51.
  13. Chiu CG, Chan SK, Fang ZA, Masoudi H, Wood-Baker R, Jones SJ, et al. Beta-catenin expression is prognostic of improved non–small cell lung cancer survival. Am J Surg Pathol. 2012;203(5):654-9.
  14. Zaid KW. Immunohistochemical assessment of E-cadherin and β -catenin in the histological differentiations of oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2014;15(5):8847-53.
  15. Zhang DP, Li XW, Lang JH. Prognostic Value of β -catenin Expression in Breast Cancer Patients: a Meta-analysis. Asian Pac J Cancer Prev. 2014;16(14):5625-33.
  16. Morin PJ, Sparks AB, Korine kV, Barker N, Clevers H, Vogelstein B, Kinzler KW 1997 Activation of β –catenin -Tcf signaling in colon cancer by mutations in -catenin or APC. Science 275:1787–1790
  17. Chan EF, Gat U, McNiff JM, Fuchs E 1999 A common human skin tumour is caused by activating mutations in β –catenin . Nat Genet 21:410–413
  18. de La Coste A,Romagnolo B,Billuart P,Renard CA,Buendia MA,Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C 1998 Somatic mutations of the β -catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95:8847–8851
  19. Jargin S. Book review: Dabbs DJ. Diagnostic immunohistochemistry. Elsevier [Russian]. Ukrainian Med J 2010;78:96‑8.
  20. Kikuchi A, Yamamoto H. Tumor formation due to abnormalities in the β -catenin-independent pathway of Wnt signaling. Cancer Sci. 2008;99(2):202-8.
  21. MacDonald BT, Tamai K, He X. Wnt/β -catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):26-9. https://doi.org/10.1016/j.devcel.2009.06.016 PMID:19619488 PMCid:PMC2861485
  22. Miyake N, Maeta H, Horie S, Kitamura Y, Nanba E, Kobayashi K, et al. Absence of mutations in the β‐catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. Pathol Int 2001;51:680‑5.
  23. Bełdowski M. Assessment of plasma B‑catenin concentration as biomarker of thyroid cancer. Pol Przegl Chir 2015;87:340‑5
  24. Kurihara T, Ikeda S, Ishizaki Y, Fujimori M, Tokumoto N, Hirata Y, et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid 2004;14:1020‑9.
  25. Dabbs DJ. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. Philadelphia, PA : Elsevier Health Sciences; 2018.
  26. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422-6.
  27. Zhang J, Gill AJ, Issacs JD, Atmore B, Johns A, Delbridge LW, et al. The Wnt/β -catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. Hum Pathol. 2012;43(7):1044-50.
  28. Rossi ED, Straccia P, Palumbo M, Stigliano E, Revelli L, Lombardi CP, et al. Diagnostic and prognostic role of HBME-1, galectin-3, and β -catenin in poorly differentiated and anaplastic thyroid carcinomas. Appl Immunohistochem Mol Morphol. 2013;21(3):237-41. PMID:23235344
  29. Cooper DS, Doherty GM, Hauger BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009;19(11):1167- 214.
  30. Udelsman R. Treatment of persistent or recurrent papillary carcinoma of the thyroid—the good, the bad, and the unknown. J Clin Endocrinol Metab. 2010;95(5):2061-3.
  31. Machens A, Hauptmann S, Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery. 2009;145(2):176-81.
  32. Melck A, Masoudi H, Griffith OL, Rajput A, Wilkins G, Bugis S, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol. 2007;14(12):3403-11. PMID:17882495
  33. Zablotska LB, Ron E, Rozhko AV, Hatch M, Polyanskaya ON, Brenner AV, et al. Thyroid cancer risk in Belarus among children and adolescents exposed to radioiodine after the Chornobyl accident7. https://doi.org/10.1038/sj.bjc.6605967 PMID:21102590 PMCid:PMC3039791
  34. Rezk S, Brynes R, Nelson V, Thein M, Patwardhan N, Fischer A, et al. β‑Catenin expression in thyroid follicular lesions: Potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol 2004;15:329‑37.
  35. Garcia‑Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. β‑catenin dysregulation in thyroid neoplasms: Down‑regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001;158:987‑96.
  36. Meirmanov S, Nakashima M, Kondo H, Matsufuji R, Takamura N, Ishigaki K, et al. Correlation of cytoplasmic β‑catenin and cyclin D1 overexpression during thyroid carcinogenesis around Semipalatinsk nuclear test site. Thyroid 2003;13:537‑45.
  37. He F, Li H, Li WS, Dong XH. Expression of mucin‑l and beta‑catenin in papillary thyroid carcinoma and the clinical significance thereof. Zhonghua Yi Xue Za Zhi 2009;89:393‑6
  38. Ligon LA, Karki S, Tokito M, et al. Dynein binds to beta-catenin and may tether microtubules at adherens junctions. Nat Cell Biol 3(10):913–917, 2001.